• SENSEX
    NIFTY 50
Market

These are Wednesday's biggest brokerage calls: IndusInd Bank, Wipro and more

Updated : 2020-01-15 08:18:18

Indian shares are expected to open on a flat note on Wednesday as global cues remain muted as market participants await the US-China trade deal. Among brokerages, Credit Suisse is 'neutral' on Wipro, while Citi and Macquarie are bullish on IndusInd Bank: Here are the top brokerage calls for Wednesday:

 Credit Suisse on Wipro:  The brokerage maintained a 'neutral' call on the stock with a target at Rs 250 per share. It added that positives include a steady decline in attrition over the last two quarters.
Credit Suisse on Wipro: The brokerage maintained a 'neutral' call on the stock with a target at Rs 250 per share. It added that positives include a steady decline in attrition over the last two quarters.
 Citi on IndusInd Bank:  The brokerage had a 'buy' target on the stock and raised its target to Rs 1,900 per share form Rs 1,800 earlier. The company's core operations would likely remain strong which can support higher provisions, it further noted.
Citi on IndusInd Bank: The brokerage had a 'buy' target on the stock and raised its target to Rs 1,900 per share form Rs 1,800 earlier. The company's core operations would likely remain strong which can support higher provisions, it further noted.
 Macquarie on IndusInd Bank : The brokerage had an 'outperform' call on the stock with a target at Rs 1,850 per share. As per the brokerage, the good news was that the bank’s exposure to three stressed groups declined further.
Macquarie on IndusInd Bank: The brokerage had an 'outperform' call on the stock with a target at Rs 1,850 per share. As per the brokerage, the good news was that the bank’s exposure to three stressed groups declined further.
 Morgan Stanley on IndusInd Bank:  The brokerage was 'overweight' on the stock with a target at Rs 1,800 per share. Uncertain asset quality could keep the stock volatile in the near term, it added.
Morgan Stanley on IndusInd Bank: The brokerage was 'overweight' on the stock with a target at Rs 1,800 per share. Uncertain asset quality could keep the stock volatile in the near term, it added.
 Nomura on IndusInd Bank:  The brokerage retained a 'buy' rating on the stock with a target at Rs 1,750 per share. It added that the bank's pre-provision operating profit (PPoP) outlook was improving, but it was not out of the woods on the corporate credit front.
Nomura on IndusInd Bank: The brokerage retained a 'buy' rating on the stock with a target at Rs 1,750 per share. It added that the bank's pre-provision operating profit (PPoP) outlook was improving, but it was not out of the woods on the corporate credit front.
 IDFC Securities on IndusInd Bank:  The brokerage downgraded the stock to 'neutral' with a target at Rs 1,380 per share. It added that ratings cut on higher corporate risks as uncertainties on the corporate portfolio remain high.
IDFC Securities on IndusInd Bank: The brokerage downgraded the stock to 'neutral' with a target at Rs 1,380 per share. It added that ratings cut on higher corporate risks as uncertainties on the corporate portfolio remain high.
 Nomura on Bandhan Bank:  The brokerage maintained a 'neutral' call on the stock with a target price cut to Rs 585 from Rs 625 earlier. It added that earnings were marginally weaker than expected.
Nomura on Bandhan Bank: The brokerage maintained a 'neutral' call on the stock with a target price cut to Rs 585 from Rs 625 earlier. It added that earnings were marginally weaker than expected.
 Morgan Stanley on JSPL:  The brokerage was 'overweight' on the stock with a target at Rs 174 per share. If Angul’s operations stabilise and sustained, it could drive incremental volumes, the brokerage noted.
Morgan Stanley on JSPL: The brokerage was 'overweight' on the stock with a target at Rs 174 per share. If Angul’s operations stabilise and sustained, it could drive incremental volumes, the brokerage noted.
 Credit Suisse on Sun Pharma:  The brokerage was 'neutral' on the stock with a target at Rs 450 per share. It stated that competition was likely to intensify in the US psoriasis market.
Credit Suisse on Sun Pharma: The brokerage was 'neutral' on the stock with a target at Rs 450 per share. It stated that competition was likely to intensify in the US psoriasis market.
Live TV
Advertisement